Drug intelligence / Profile preview

anti-siglecf antibody

Development stage
Preclinical
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Anti-SiglecF antibody is a monoclonal antibody directed against Siglec-F, a sialic acid-binding immunoglobulin-like lectin primarily expressed on mouse eosinophils. The antibody works by engaging and cross-linking Siglec-F on eosinophils, leading to induction of apoptosis and depletion of eosinophils in vivo and in vitro. Siglec-F is the closest functional paralog of human Siglec-8, which is also a target for anti-eosinophil therapies. Studies in mice demonstrate that administration of anti-SiglecF antibody results in a rapid and significant decrease in blood and tissue eosinophils via selective induction of eosinophil cell death, supporting potential therapeutic applications in mouse models of eosinophil-associated diseases. This antibody is primarily a research and preclinical tool in murine disease models, not a clinical drug for humans[1][12].

Other names
anti-siglec-f antibodyanti-siglec F antibodyanti-mouse siglec-f antibodysiglec-f antibody
02

Targets

Siglec (Siglec family)

Beyond the preview

Go deeper on anti-siglecf antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-siglecf antibody.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call